Physician profile
Amir A Ahmadi
NPI 1154778900
$788,849.52
in general payments reported to CMS, 2019-2025
22 companies · $666K in 2025
The $666K reported for 2025 was more than what 99% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.00 · 2020: $549 · 2021: $453 · 2022: $435 · 2023: $556 · 2024: $121K · 2025: $666K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $786K · Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $786,162.04 |
| Food and Beverage | $1,197.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elucid Bioimaging INC | $786,162.04 | 2024-2025 | Plaqueiq |
| Amgen INC. | $506.10 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $440.22 | 2021-2025 | |
| Heartflow, INC. | $392.15 | 2019-2023 | Ffrct |
| Boston Scientific Corporation | $276.38 | 2021-2022 | |
| Pfizer INC. | $143.28 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $124.29 | 2020-2025 | Farxiga, Lokelma, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $123.38 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $112.45 | 2020-2023 | Xarelto |
| Scpharmaceuticals INC. | $102.37 | 2025 | |
| Merck Sharp & Dohme LLC | $82.64 | 2023-2024 | Verquvo |
| Bardy Diagnostics, INC. | $70.83 | 2021 | |
| Novo Nordisk INC | $52.62 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $41.57 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $38.26 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procyrion, INC. | $32.94 | 2024 | |
| Philips North America LLC | $29.75 | 2024 | (Br3) Coronary Other |
| Esperion Therapeutics, INC. | $28.98 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.31 | 2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $25.83 | 2025 | Camzyos |
| Abbott Laboratories | $18.29 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Lilly USA, LLC | $17.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Ahmadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.